Author

Remo Panaccione

HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY
HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY

Remo Panaccione  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 9.2 YEARS OF SAFETY DATA FROM THE GLOBAL CLINICAL PROGRAMME
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 9.2 YEARS OF SAFETY DATA FROM THE GLOBAL CLINICAL PROGRAMME

Remo Panaccione  et al.

ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION
ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION

Remo Panaccione  et al.

SYMPTOMATIC IMPROVEMENT OBSERVED WITHIN 2 DAYS OF ETRASIMOD INDUCTION THERAPY: RESULTS FROM ELEVATE UC 52 AND ELEVATE UC 12 STUDIES IN PATIENTS WITH ULCERATIVE COLITIS
SYMPTOMATIC IMPROVEMENT OBSERVED WITHIN 2 DAYS OF ETRASIMOD INDUCTION THERAPY: RESULTS FROM ELEVATE UC 52 AND ELEVATE UC 12 STUDIES IN PATIENTS WITH ULCERATIVE COLITIS

Remo Panaccione  et al.

THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 INTERIM ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY
THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 INTERIM ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY

Remo Panaccione  et al.

PRA023 IMPROVED HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY IBDQ-32 IN A PHASE 2 TRIAL FROM PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
PRA023 IMPROVED HEALTH-RELATED QUALITY OF LIFE AS MEASURED BY IBDQ-32 IN A PHASE 2 TRIAL FROM PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Remo Panaccione  et al.

COMPARATIVE EFFICACY AND SAFETY OF UPADACITINIB, VEDOLIZUMAB, USTEKINUMAB AND TOFACITINIB AFTER ONE-YEAR MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: 3 MATCHING-ADJUSTED INDIRECT COMPARISONS
COMPARATIVE EFFICACY AND SAFETY OF UPADACITINIB, VEDOLIZUMAB, USTEKINUMAB AND TOFACITINIB AFTER ONE-YEAR MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: 3 MATCHING-ADJUSTED INDIRECT COMPARISONS

Remo Panaccione  et al.

RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES
RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES

Remo Panaccione  et al.

ENDOSCOPIC AND HISTOLOGIC IMPROVEMENTS WITH PRA023 IN ARTEMIS-UC, A PHASE 2 PLACEBO-CONTROLLED STUDY ON MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
ENDOSCOPIC AND HISTOLOGIC IMPROVEMENTS WITH PRA023 IN ARTEMIS-UC, A PHASE 2 PLACEBO-CONTROLLED STUDY ON MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Remo Panaccione  et al.

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY

Remo Panaccione  et al.

MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
MATCHING-ADJUSTED INDIRECT COMPARISONOF UPADACITINIB VERSUS VEDOLIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Remo Panaccione  et al.

CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS
CLINICAL AND ENDOSCOPIC IMPROVEMENTS WITH RISANKIZUMAB INDUCTION AND MAINTENANCE DOSING VERSUS PLACEBO ARE OBSERVED IRRESPECTIVE OF NUMBER OF PRIOR FAILED BIOLOGICS

Remo Panaccione  et al.

EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE
EFFICACY OUTCOMES BY SYMPTOM-BASED RESPONSE STATUS AFTER INDUCTION: WEEK-48 RESULTS FROM THE GALAXI 1 TRIAL OF GUSELKUMAB IN CROHN’S DISEASE

Remo Panaccione  et al.

ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 BERGAMOT STUDY
ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM THE PHASE 3 BERGAMOT STUDY

Remo Panaccione  et al.

BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE

Remo Panaccione  et al.

EFFICACY OF UPADACITINIB FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE BY DISEASE DURATION: A POST HOC ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES
EFFICACY OF UPADACITINIB FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE BY DISEASE DURATION: A POST HOC ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Remo Panaccione  et al.

SERUM PROTEIN PROFILES DIFFER WITH USTEKINUMAB AND ADALIMUMAB TREATMENT IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
SERUM PROTEIN PROFILES DIFFER WITH USTEKINUMAB AND ADALIMUMAB TREATMENT IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Remo Panaccione  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Remo Panaccione  et al.

TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY
TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY

Remo Panaccione  et al.

AN ARTIFICIAL INTELLIGENCE SYSTEM TO DETECT HISTOLOGICAL REMISSION AND PREDICT CLINICAL OUTCOMES IN ULCERATIVE COLITIS PATIENTS
AN ARTIFICIAL INTELLIGENCE SYSTEM TO DETECT HISTOLOGICAL REMISSION AND PREDICT CLINICAL OUTCOMES IN ULCERATIVE COLITIS PATIENTS

Remo Panaccione  et al.

Item 61 - 80 / 82
1 2 3
4
5